Wells Fargo’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10
| Closed | -$215 | – | 7764 |
|
|
2024
Q1 | $215 | Hold |
10
| – | – | ﹤0.01% | 6483 |
|
|
2023
Q4 | $37 | Buy |
10
+1
| +11% | +$4 | ﹤0.01% | 7013 |
|
|
2023
Q3 | $35 | Hold |
9
| – | – | ﹤0.01% | 7022 |
|
|
2023
Q2 | $38 | Sell |
9
-2
| -18% | -$6 | ﹤0.01% | 7129 |
|
|
2023
Q1 | $32 | Hold |
11
| – | – | ﹤0.01% | 7241 |
|
|
2022
Q4 | $54 | Buy |
11
+1
| +10% | +$4 | ﹤0.01% | 6987 |
|
|
2022
Q3 | $0 | Sell |
10
-394
| -98% | -$3.42K | ﹤0.01% | 7753 |
|
|
2022
Q2 | $3K | Buy |
404
+384
| +1,920% | +$3.49K | ﹤0.01% | 6262 |
|
|
2022
Q1 | $0 | Buy |
20
+19
| +1,900% | +$483 | ﹤0.01% | 8170 |
|
|
2021
Q4 | $0 | Buy |
+1
| New | +$105 | ﹤0.01% | 8097 |
|
|
2021
Q3 | – | Sell |
-953
| Closed | -$110K | – | 7773 |
|
|
2021
Q2 | $110K | Buy |
953
+756
| +384% | +$84.3K | ﹤0.01% | 5273 |
|
|
2021
Q1 | $19K | Buy |
+197
| New | +$25.7K | ﹤0.01% | 6183 |
|
Wells Fargo's LABP Position: Q2 2024 in Review
Wells Fargo sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 10 shares — an estimated $215 sold.
Wells Fargo first reported a position in LABP in Q1 2021 and held it in 12 quarters. The position peaked at $110K in Q2 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.
- Wells Fargo reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 10 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $215.
- Wells Fargo first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Wells Fargo's Landos Biopharma, Inc. Common Stock position peaked at $110K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.